A method and a non-rate controlled, monolithic, subsaturated patch for transdermally administering fentanyl and analogs thereof, for analgetic purposes, to a subject through skin over an extended period of time are disclosed.

A transdermal administration device packaged body includes a transdermal administration device including an administration member housed in a container, the administration member having at least one projection protruding from a first surface of a substrate, and an outer package which houses the transdermal administration device and has a bag form including a front component and a rear component. The front component is positioned on a first surface side of the substrate, the rear component is positioned on a second surface side opposite to the first surface side of the substrate, and the front component has an opening member configured to be pulled open to open the outer package.

The present invention is directed to transdermal therapeutic systems that are free of fibrous constituents, as well methods for producing such transdermal therapeutic systems. A preparation containing active substance is applied by a printing method onto the pressure-sensitive adhesive layer of the transdermal therapeutic system. Exemplary printing methods include application methods based upon a distributor plate of an application device.

A bioelectrode sheet (100) is configured to be affixed to the skin of a subject, a drug (104b) being mixed in an adhesive layer (104) provided at a peripheral position of a conductive gel layer (103) so as to avoid the conductive gel layer (103). The drug (104b) admixed with the adhesive layer (104) can thereby be caused to penetrate the body while biological information is acquired by an electrode (102) via the conductive gel layer (103).

Formulations for topical compositions which may be used to deliver drugs. The formulations may be used with a wearable drug delivery device for transdermal delivery. The composition may comprise a clay carrier such as kaolin and/or halloysite, loaded with one or more target compositions. The composition may comprise about 5 to about 15 percent by weight kaolin; about 5 to about 15 percent by weight oil carrier; about 2 to about 3 percent by weight essential oil; about 6.5 to about 26 percent by weight emollient; about 15 to about 20 percent by weight aloe vera barbadensis juice gel; about 0.9 percent to about 5 percent by weight thickening agent; about 0.1 percent to about 5 percent by weight stabilizer; about 2 percent to about 8 percent by weight surfactant; about less than 1 percent by weight target compound; about 0.35 to about 1.8 percent by weight preservative; and about 1 percent to about 5 percent by weight water.

A method for treating patients with COVID-19 and/or other respiratory conditions includes administering eighty-five milligrams of dapsone twice daily for twenty-one days. A variety of dapsone formulations and delivery devices are disclosed, including an inhaler, nasal spray, nasal gel, otic formulation, intravenous formulation, oral solution, oral suspension, patch and suppository.

The present invention provides a gel patch having a paste layer on a support, wherein the paste layer comprising ketoprofen or a pharmaceutically acceptable salt thereof, propylene glycol, 1-menthol, and water, wherein the mass of propylene glycol in the paste layer is 3-fold the mass of ketoprofen or less, and wherein the content of 1-menthol based on a total mass of the paste layer is 0.1 to 0.5 mass %.

The invention relates to a pharmaceutical patch comprising a Lidocaine constituent and a Diclofenac constituent, wherein the relative weight content ratio of the Lidocaine constituent to the Diclofenac constituent is within the range of from about 7:1 to about 4:1, based on the equivalent weight of the non-salt form of Lidocaine and of Diclofenac, for use in the local treatment or prevention of pain. The pharmaceutical composition is suitable for topical administration and local pharmacological action via delivery of Lidocaine and Diclofenac into the skin and possibly also through and to other deeper tissues such as the synovial fluid without significant systemic exposure.

A method for producing a patch comprising a support layer and an adhesive agent layer comprises: a mixture preparation step of mixing asenapine or a pharmaceutically acceptable salt thereof with sodium acetate whose particle diameter D.sub.50 at a cumulative volume of 50% in a particle diameter distribution is 40 to 1000 m, in such a manner that the sodium acetate and sodium diacetate generated from the sodium acetate have a particle diameter D.sub.50 of 10 m or smaller, thereby obtaining a mixture containing the sodium diacetate and the asenapine or pharmaceutically acceptable salt; and an adhesive-agent-layer formation step of forming the adhesive agent layer comprising the sodium diacetate, the asenapine or pharmaceutically acceptable salt, and a pressure-sensitive adhesive base agent, by using an adhesive agent layer composition obtained by mixing the mixture with the pressure-sensitive adhesive base agent.

This invention discloses a pharmaceutical formula for arthritis treatment and/or prevention. The formula contains the following raw materials: a selenium-containing inorganic compound and a zinc-containing inorganic compound. The pharmaceutical formula described herein could be manufactured for topic application and provide a faster and safer treatment for various inflammatory joint pains. Pharmacodynamics results show that the invented pharmaceutical formula can significantly reduce the level of inflammatory cytokines in the joint synovial fluid in arthritis rabbit model, and the formulated ointment can achieve better efficacy compared with Voltaren (diclofenac) ointment; therefore the proposed formula has promising clinical application.